Inhibition of discoidin domain receptors by imatinib prevented pancreatic fibrosis demonstrated in experimental chronic pancreatitis model by Bansod, Sapana et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2021 
Inhibition of discoidin domain receptors by imatinib prevented 
pancreatic fibrosis demonstrated in experimental chronic 
pancreatitis model 
Sapana Bansod 
Mohd Aslam Saifi 
Chandraiah Godugu 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
1
Vol.:(0123456789)
Scientific Reports |        (2021) 11:12894  | https://doi.org/10.1038/s41598-021-92461-z
www.nature.com/scientificreports
Inhibition of discoidin domain 
receptors by imatinib prevented 
pancreatic fibrosis demonstrated 
in experimental chronic 
pancreatitis model
Sapana Bansod2, Mohd Aslam Saifi1 & Chandraiah Godugu1*
Discoidin domain receptors (DDR1 and DDR2) are the collagen receptors of the family tyrosine 
kinases, which play significant role in the diseases like inflammation, fibrosis and cancer. Chronic 
pancreatitis (CP) is a fibro-inflammatory disease in which recurrent pancreatic inflammation leads 
to pancreatic fibrosis. In the present study, we have investigated the role of DDR1 and DDR2 in CP. 
The induced expression of DDR1 and DDR2 was observed in primary pancreatic stellate cells (PSCs) 
and cerulein-induced CP. Subsequently, the protective effects of DDR1/DDR2 inhibitor, imatinib 
(IMT) were investigated. Pharmacological intervention with IMT effectively downregulated DDR1 
and DDR2 expression. Further, IMT treatment reduced pancreatic injury, inflammation, extracellular 
matrix deposition and PSCs activation along with inhibition of TGF-β1/Smad signaling pathway. Taken 
together, these results suggest that inhibition of DDR1 and DDR2 controls pancreatic inflammation 
and fibrosis, which could represent an attractive and promising therapeutic strategy for the treatment 
of CP.
Abbreviations
CP  Chronic pancreatitis
CTGF  Connective tissue growth factor
DDRs  Discoidin domain receptors
ECM  Extracellular matrix
IMT  Imatinib
NF-κB  Nuclear factor kappa B
PSCs  Pancreatic stellate cells
PDGF  Platelet-derived growth factor
α-SMA  α-Smooth muscle actin
TGF-β  Transforming growth factor-β
Chronic pancreatitis (CP) is a fibro-inflammatory disease of the pancreas, characterized by recurrent pancreatic 
inflammation and fibrosis leading to irreversible impairment of exocrine and endocrine functions of  pancreas1. 
CP is a major risk factor for the progression of diabetes and pancreatic cancer in the developed  countries2. 
Although there has been an extensive research in CP during last few years, but the exact pathogenesis and spe-
cific molecular mechanism of CP needs to be elucidated. The well-established theory behind CP development 
is premature activation of pancreatic digestive enzymes leading to autodigestion of pancreatic tissue and the 
recruitment of the excess inflammatory cells that results in pancreatic  inflammation3. Pancreatic fibrosis is a 
complex pathological event in which wherein dysregulation of production and degradation of extracellular matrix 
(ECM) is observed in the pancreas. Persistent inflammation causes the activation of pancreatic fibroblasts, known 
as pancreatic stellate cells (PSCs) which promote development of pancreatic fibrosis. Upon activation, PSCs 
undergo morphological changes and initiate pancreatic fibro-inflammation through the secretion of a number of 
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inflammatory mediators and excessive synthesis of ECM proteins such as collagen I, III and  fibronectin4. Among 
these mediators, transforming growth factor (TGF)-β1 is the potent profibrotic cytokine which regulates PSCs 
activation and pancreatic fibrogenesis through its downstream Smad signaling  pathway5. Currently, CP treatment 
is only limited to the supportive care and there is no clinically available therapeutic agent to treat CP and associ-
ated fibrosis progression. Thus, there is a pressing need to identify novel therapeutic agents for the treatment of 
CP on high priority, which could be helpful to reduce costs of long-term therapy and improve the quality of life.
Discoidin domain receptors (DDR1 and DDR2) are new class of tyrosine kinase receptors, which get activated 
in response to collagens and are involved in the early embryonic  development6. DDR1 is majorly expressed in 
epithelial cells and activated by both fibrillar and nonfibrillar collagens (type I to V, VIII, and XI), while DDR2 
is expressed in fibroblasts and activated by fibrillar collagens (type I and III). This binding causes phosphoryla-
tion and dimerization of the tyrosine kinase receptors which then leads to the activation of different signaling 
pathways involved in inflammation and  fibrosis7. Accumulating evidences have reported that upregulated expres-
sion of DDR1 and DDR2 are observed in the chronic injury, inflammation and fibrotic  conditions8. Multiple 
studies reported that inhibition of DDR1 reduced deposition of collagen I and IV in alcoholic liver fibrosis, lung 
fibrosis, cirrhotic liver and chronic  nephropathies9–11. On the other hand, DDR2 is a key regulator of epithelial 
to mesenchymal transition (EMT) program, which is involved in several pathological changes such as fibrosis 
and tumor  progression12. Although, the DDRs are involved in inflammatory and fibrotic diseases but their role 
in CP and associated fibrosis is not explored fully.
Imatinib mesylate (IMT) is a standard Food and Drug Administration (FDA)-approved drug for the treatment 
of patients with chronic myelocytic leukemia. IMT is the only tyrosine kinase inhibitor which potentially inhibits 
both the profibrotic cytokines, TGF-β and PDGF which are involved in regulation of organ fibrosis process. 
Emerging studies have shown that IMT has the potent tyrosine kinase DDR1 and DDR2 inhibitory  activity13. 
IMT is the type-2 DDRs inhibitor which inhibits tyrosine kinase domain by leveraging the ATP binding site as 
well as the allosteric site, which is freely accessible in the inactive  conformation14. However, the effect of IMT 
on CP has not been studied yet and the underlying molecular mechanism remains to be explored. Therefore, in 
the present study, we investigated the role of DDR1 and DDR2 in progression of CP and associated fibrosis. In 
addition, we investigated the protective effects of pharmacological inhibitor of DDR1 and DDR2, IMT against 
CP and pancreatic fibrosis. Our results showed that inhibition of DDR1 and DDR2 signaling by IMT could 
effectively attenuate CP and associated fibrosis and further indicate that DDR1 and DDR2 could be the potential 
therapeutic targets for treatment of CP.
Materials and methods
Reagents. Imatinib mesylate (IMT) was procured from Sigma Aldrich, USA. Cerulein was obtained from 
Ana Spec, France. TGF-β1 was procured from Bio-legend, USA. The antibodies viz. β-actin (Catalogue no. 
sc-47778), Collagen1a (Catalogue no. sc-393573), Collagen3a (Catalogue no. sc-271249), α-SMA (Catalogue no. 
sc-53142), CTGF (Catalogue no. sc-373936), TGF-β1 (Catalogue no. sc-146), DDR2 (Catalogue no. sc-81707), 
pSmad2/3 (Catalogue no. #8828), Smad2/3 (Catalogue no. #8685), pDDR1 (Catalogue no. #14531), DDR1 (Cat-
alogue no. #5583), pNF-κB (Catalogue no. #3033), NF-κB (Catalogue no. #8242) were procured from Santa 
Cruz Biotechnology Ltd and Cell Signaling Technology, USA. The ELISA kits of TGF-β, IL-1β, IL-6 and TNF-α 
(Catalogue no. TGF-β: 88–8350, IL-1β: 88–7013, IL-6: 88- 7064, and TNF-α: 88–7324) were obtained from 
eBioscience, USA.
PSCs isolation, culture and treatment. PSCs were isolated from the mice according to the methods as 
described with slight  modifications15. Briefly, pancreas was isolated from adult male Swiss albino mice. Isolated 
pancreas was immediately washed in sterile PBS. A small portion of pancreas was cut, minced with scissors and 
single cell suspension was prepared using 1 ml syringe in Dulbecco’s Modified Eagle medium (DMEM). Next, 
cell suspension was centrifuged followed by two times washing with PBS. Cell’s pellet was mixed and cultured in 
DMEM medium containing 1% antibiotic solution and supplemented with 20% fetal bovine serum (FBS). PSCs 
were separated by using the Histodenz density gradient centrifugation  method16.
Oil-red O staining for PSCs identification. After 70% confluency, PSCs were fixed with 4% paraform-
aldehyde and 0.1% Triton X-100 reagents and stained with oil-red O working solution (1% in isopropanol) at 60 
℃ for 30 min. Next, PSCs were counterstained using hematoxylin, mounted with mounting medium, Dibutyl-
phthalate Polystyrene Xylene (DPX) and observed under the  microscope17.
Confocal microscopy. Freshly isolated and cultured PSCs were treated with IMT (1 μM) in the presence 
or absence of TGF-β1 (10 ng/ml). After 24 h of treatment, cells were fixed with 4% paraformaldehyde and 0.1% 
Triton X-100 followed by blocking with 3% bovine serum albumin (BSA) for 1 h. The cells were then labeled 
with primary antibodies against α-SMA, collagen 1a, pSmad2/3, pDDR1, and DDR2 at 4 °C for overnight. Next 
day, cells were probed with secondary antibody conjugated with rhodamine (1:200 dilution) or fluorescein iso-
thiocyanate (FITC) (1:100 dilution) for 1 h. After washing, cells were mounted with fluoroshield 4′,6-diamidino-
2-phenylindole (DAPI) (Sigma-Aldrich, USA) medium and fluorescent signals were captured by confocal laser-
scanning microscopy (Leica, Germany)18.
Animals and experimental design. Animals were kept in well-controlled housing facility at temperature 
(25 ± 2 °C) and 12/12-h light/dark cycle with free access to water and pellet food. The Animal experiments were 
designed, conducted and reported as per the ARRIVE  guidelines19. Specifically, all the animal experiments were 
performed according to the Committee for the Purpose of Control and Supervision of Experiments on Animals 
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(CPCSEA), which is the approval body for animal experimentation in India. The CPCSEA certified Institutional 
Animal Ethical Committee (IAEC) of National Institute of Pharmaceutical Education and Research (NIPER)-
Hyderabad, has reviewed the animal protocol and approved it (IAEC Protocol Approval No.: NIP/01/2019/
RT/365).
Male Swiss albino mice (age: 6–8 weeks, body weight 25–30 g) were purchased from Palamur Biosciences 
Pvt. Ltd, Mahabubnagar, India. All mice were randomly divided into 6 groups (7 mice per group, n = 42): Normal 
control, IMT alone, Cerulein, Cerulein + IMT low dose (LD—1 mg/kg), Cerulein + IMT mid dose (MD—3 mg/
kg) and Cerulein + IMT high dose (HD—10 mg/kg). CP was induced by 6-hourly exposures of cerulein (50 μg/
kg/intraperitoneal (i.p.), 3 alternative days per week, for the period of 3 weeks as per our previously published 
 protocol20. Cerulein + IMT group mice were administered IMT (1, 3 and 10 mg/kg) orally, every other day after 
cerulein exposures for 3 weeks. Normal control animals received i.p. injection of sterile normal saline same as 
cerulein group. IMT alone group mice were administrated with IMT (10 mg/kg) orally 4 alterative days in the 
week for 3 weeks (Fig. 1). Mice were sacrificed via inhalation euthanasia  (CO2 asphyxiation) after completion 
of 21 days. Doses of IMT were selected on the basis of previous  literature21. IMT was dissolved in distilled water 
and administrated orally 4 alterative days in the week for 3 weeks. As cerulein needed minimum 12 h to produce 
its maximum inflammatory response, IMT was given every other day after cerulein exposures for a period of 
3  weeks20.
Blood collection and plasma analysis. Blood samples were collected by cardiac puncture on the day of 
sacrifice in heparin containing tubes and plasma was separated after centrifugation. Amylase and lipase levels 
were assessed in plasma and measured by using Accurex kinetic enzymatic kits and values are expressed as IU/
L20,22.
Collagen estimation by Sircol assay. Pancreatic tissues were homogenized in PBS and then superna-
tants were incubated with collagen binding dye picrosirius red for 1 h at 37 °C. Next, samples were centrifuged 
and obtained pellet was resuspended in 100% ethanol followed by centrifugation at 9168×g for 10 min. Then 
pellet was mixed with 0.5 M NaOH solution and incubated for 30 min at 37 °C. The final absorbance was taken 
at 540 nm and values were expressed as relative collagen content per milligram of  protein23.
Enzyme-linked immunosorbent assay. Cytokine concentrations in pancreas were determined by eBio-
science ELISA kits for IL-6, IL-1β, TNF-α and TGF-β1 as per the previously described  protocol24. Concentration 
of cytokines was expressed as pg per milligram of protein. Total protein was estimated by Bicinchoninic acid 
assay kit (Sigma Aldrich, USA).
Histopathology and immunohistochemistry analysis. Pancreas were fixed in 10% formaldehyde 
solution and paraffin-embedded pancreatic sections were taken at 5 µm using microtome (Leica, Germany). The 
pancreatic sections were stained with H & E, picrosirius red (PSR) and Masson’s trichrome (MT) as per previ-
ously described  protocol25. For immunostaining, antigen retrieval was carried out by citrate buffer. After wash-
ing, sections were incubated with 3% hydrogen peroxide for 15 min followed by blocking with 3% BSA. The pri-
mary antibodies against α-SMA, collagen1a, pDDR1 and DDR2 (1:100) were added and kept at 4 ℃ overnight. 
The HRP-conjugated secondary antibodies were added and sections were stained with 3, 3-diaminobenzidine 
(DAB) reagent. Further, sections were counterstained with hematoxylin and images were observed using a light 
Figure 1.  Experimental design for development and treatment of CP in mice. Male Swiss albino mice were 
randomly divided into 6 groups (7 mice per group): Normal control, IMT alone, Cerulein, Cerulein + IMT 
low dose (IMT LD—1 mg/kg), Cerulein + IMT mid dose (IMT MD—3 mg/kg) and Cerulein + IMT high dose 
(IMT HD—10 mg/kg). CP was induced by 6-hourly intraperitoneal (i.p.) injections of cerulein (50 μg/kg), 3 
alternative days per week, for the period of 3 weeks. Cerulein + IMT group mice were administered IMT (1, 3 
and 10 mg/kg) orally, every other day after cerulein exposures for 3 weeks. Normal control group mice received 
normal saline same as cerulein group. IMT alone group mice were administrated with IMT (10 mg/kg) orally 4 
alterative days in the week for 3 weeks.
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microscope (CX21i Olympus, India)26. Quantitative analysis of fibrotic and immunopositive area were analyzed 
using ImageJ software (NIH, USA).
Immunoblotting. To analyze the pancreas protein expression, immunoblotting technique was used as 
described  earlier27,28. Small portions of pancreatic tissues were homogenized in RIPA lysis buffer. Then equal 
amounts of proteins were separated using SDS-PAGE gel electrophoresis and transferred to a nitrocellulose 
membrane. The protein blots were then detected using ECL (Bio-Rad Laboratories, USA) and densitometric 
analysis of respective protein bands was carried out by ImageJ software (NIH, USA).
Statistical analysis. All results are given as mean ± SEM. Student’s t-test was used to determine the differ-
ence between two groups. However, differences among more than two groups were analyzed using nonparamet-
ric test one-way analysis of variance by GraphPad Prism scientific software version 6.01. Value of P less than 0.05 
was considered statistically significant.
Results
Upregulation of DDR1 and DDR2 expression in pancreatic fibrosis. We evaluated the expression 
of DDR1 and DDR2 via western blot and immunohistochemical analysis in CP mice. Interestingly, we found 
marked upregulation of phosphorylated DDR1, DDR2 and collagen1a expression in pancreatic tissue of CP mice 
(Fig. 2A–D, Supplemental Fig. S1). In addition, immunohistochemical (IHC) staining and quantification analy-
sis demonstrated that expression of DDR1 and DDR2 was significantly increased in CP model mice as compared 
to the normal control mice (Fig. 2E). These results indicated the upregulation of DDR1 and DDR2 receptors in 
the progression of CP and associated pancreatic fibrosis.
Inhibition of DDR1 and DDR2 prevents progression of pancreatic fibrosis. Next, to investigate 
whether collagen receptors DDR1 and DDR2 play key role in the development of CP and associated fibrosis or 
not, we evaluated the effects of DDR1/DDR2 inhibitor, IMT in cerulein-induced CP model. Treatment with 
IMT (1, 3 and 10 mg/kg) showed significant downregulation of phosphorylated DDR1 and DDR2 expression in 
a dose-dependent manner (Fig. 3A–C, Supplemental Fig. S2). In addition, we found that cerulein-treated mice 
demonstrated significantly higher collagen expression, whereas oral administration of IMT dose-dependently 
reduced collagen expression as compared to cerulein-control mice (Fig. 3D,E). We further assessed the effects 
of IMT on TGF-β1-induced PSCs activation by confocal microscopy. Our results demonstrated that TGF-β1-
treated PSCs showed notably upregulated pDDR1, DDR2 and collagen1a expression and the expression of these 
proteins was markedly inhibited by IMT treatment (Fig. 3F,G). Together, these results suggest that inhibition of 
DDR1 and DDR2 expression suppressed collagen deposition and pancreatic fibrosis.
Figure 2.  Upregulation of DDR1 and DDR2 in pancreatic fibrosis. (A–D) Western blot and corresponding 
densitometric analysis of protein expression of phosphorylated DDR1, total DDR1, DDR2 and collagen1a in 
pancreatic tissue. (E) Representative photographs of immunohistochemistry of phosphorylated DDR1 and 
DDR2 in the pancreatic tissue. β-actin was used as loading control. All values are represented as mean ± SEM 
(n = 3–10). Statistical significance was established using Student’s t-test where **P < 0.01, ***P < 0.001 vs Normal 
control. Full-length blots are presented in Supplementary Fig. S1.
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IMT controls collagen deposition in the pancreas. IHC staining and their quantification analysis 
showed that the expression of DDR1, DDR2 and collagen1a were strongly increased in CP mice. However, IMT 
treatment prevented the elevated pancreatic DDR1, DDR2, and collagen1a expression as confirmed by IHC 
analysis (Fig. 4A–C). Further, pancreatic sections of cerulein-treated mice showed marked pancreatic fibrosis 
illustrated by red and blue color in PSR and MT staining, respectively around the pancreatic ducts. Interestingly, 
treatment with DDRs inhibitor, IMT significantly attenuated collagen deposition in the pancreas (Fig. 4D,E). 
In addition, Sircol assay was performed to measure total collagen content in the pancreas. Our results demon-
strated that CP mice demonstrated significantly increased collagen content and this collagen content was effec-
tively reduced by IMT treatment (Fig. 4F).
IMT attenuates cerulein-induced pancreatic injury and inflammation. Next, we investigated the 
protective effects of IMT against cerulein-induced CP model. Cerulein challenged mice demonstrated signif-
icant elevation in plasma amylase and lipase levels, while IMT administration effectively reduced these lev-
els (Fig. 5A,B). Further, to evaluate the anti-inflammatory effects of IMT, histopathological examination was 
performed in the pancreatic tissue by H&E staining. Our results revealed that the hallmark characteristics of 
CP including acinar cell atrophy, vacuolization, inflammatory cells infiltration and collagen deposition were 
observed in the cerulein control pancreas. On the other hand, pharmacological intervention with IMT mark-
edly ameliorated cerulein-induced histopathological alterations as shown in Fig. 5C. These results suggest that 
IMT attenuated cerulein-induced pancreatic injury in CP mice. Furthermore, we examined the effect of IMT 
on NF-κB p65 expression by western blot analysis. We found that the expression of phosphorylated NF-κB p65 
was significantly increased in cerulein challenged mice, while IMT mid dose and high dose mice demonstrated 
significant inhibition of phosphorylated NF-κB expression in the pancreatic tissues (Fig. 5D,E, Supplemental 
Fig. S3). In addition to this, we observed that repetitive cerulein exposure significantly increased the cytokine 
production in the pancreas, while IMT treatment markedly suppressed these cytokines levels, indicating down-
regulation of local production of pro-inflammatory cytokines (Fig. 5F–H). Collectively, our results indicated 
that IMT shows potent anti-inflammatory effects and prevent pancreatic injury in CP mice.
IMT inhibits the activation of PSCs studied in-vivo and in-vitro model. PSCs activation is a major 
event involved in the synthesis and accumulation of ECM proteins resulting in the development of pancreatic 
fibrosis. In response to chronic injury, quiescent PSCs convert to an activated PSCs synthesizing excessive ECM 
proteins. Our in-vivo results showed that the expression of α-SMA was profoundly increased in cerulein-treated 
CP mice, indicating increased number of activated PSCs during CP. On the other hand, pharmacological treat-
ment with IMT significantly inhibited the PSCs activation as demonstrated by downregulation of α-SMA expres-
sion in the pancreas (Fig. 6A–D, Supplemental Fig. S4). Consistent with the in-vivo results, we observed marked 
upregulation of α-SMA expression in TGF-β1-stimulated mouse PSCs. However, treatment with IMT success-
Figure 3.  Inhibition of DDR1 and DDR2 expression prevents progression of pancreatic fibrosis. (A–E) 
Western blot and corresponding densitometric analysis of protein expression of phosphorylated DDR1, total 
DDR1, DDR2, collagen1a and collagen3a in pancreatic tissue. (F–H) Immunofluorescence (IF) staining for 
phosphorylated DDR1, DDR2 and collagen1a in TGF-β1-induced PSCs. β-actin was used as loading control. 
All values are represented as mean ± SEM (n = 3). Statistical significance was established using one-way ANOVA 
followed by Tukey’s multiple comparisons test where ***P < 0.001 vs Normal control, ###P < 0.001 vs Cerulein. 
Full-length blots are presented in Supplementary Fig. S2.
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fully decreased α-SMA expression, indicating the effective inhibition of PSCs activation by IMT (Fig. 6E). These 
results clearly indicated that IMT successfully inhibited PSCs activation.
IMT inhibits TGF-β/Smad signaling. TGF-β/Smad is a well-established fibrotic signaling pathway which 
gets activated in response to the injuries (Fig. 7A, Supplemental Fig. S5). Further, we found that IMT treatment 
significantly downregulated the expression of phosphorylated Smad2/3 in CP mice (Fig.  7B). In addition to 
this, our results demonstrated that there was a significant increase in TGF-β1 expression in cerulein- chal-
lenged mice. Treatment with IMT significantly inhibited expression of TGF-β1 in a dose-dependent manner 
(Fig. 7C,D). Furthermore, our western blot results revealed the expression of CTGF was markedly increased 
in cerulein-induced CP mice, which was effectively inhibited by IMT treatment (Fig. 7E). On the other hand, 
TGF-β1-induced PSCs also showed marked increase in phosphorylated Smad2/3 expression and this expression 
was effectively downregulated by IMT treatment (Fig. 7F). Taken together, these results indicated that IMT sig-
nificantly inhibited TGF-β/Smad signaling in CP model and in PSCs.
Discussion
CP is a fibro-inflammatory disease which is majorly associated with abnormal synthesis and deposition of ECM 
in the pancreas leading to the development of pancreatic  fibrosis18,20,25. Although, there are multiple signaling 
pathways involved in the pathogenesis of CP, activation of collagen-producing PSCs is the foremost event in 
the progression of pancreatic fibrosis. PSCs are the main cells of pancreas involved in the ECM deposition and 
Figure 4.  IMT controls collagen deposition in the pancreas (A–C) Representative photographs and 
quantitative analysis of immunohistochemistry of phosphorylated DDR1, DDR2 and collagen1a protein, 
(D,E) Representative photographs and quantitative analysis of PSR and MT staining in the pancreatic tissue, 
(F) Relative collagen content in pancreas estimated by Sircol assay. All values are represented as mean ± SEM 
(n = 10). Statistical significance was established using one-way ANOVA followed by Tukey’s multiple 
comparisons test where ***P < 0.001 vs Normal control, #P < 0.05, ###P < 0.001 vs Cerulein.
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activation of fibrotic signaling during pancreatic fibrosis. It is well-known that TGF-β1, a profibrotic cytokine 
induces the activation of PSCs resulting in excess synthesis and secretion of collagen by PSCs consequently 
leading to pancreatic  fibrosis29.
Collagen-activated receptors, DDRs gained a considerable amount of attention because of their involvement 
in the multiple pathological conditions and are classified into 2 types: DDR1 and  DDR230–32. These receptors 
are majorly involved in both physiological as well as pathological  processes33. Recently, studies have reported 
that collagen receptors DDR1 and DDR2 play a central role in the regulation of inflammation and fibrotic 
 conditions34,35. Apart from this, DDR1 and DDR2 receptors also play a decisive role in the activation of myofi-
broblasts and TGF-β/Smad signaling which is majorly involved in the initiation and progression of  fibrosis36. 
The hallmark feature of DDRs is that they are directly activated upon binding to components of ECM proteins 
which then activates inflammatory and fibrotic signaling  pathways37. Notwithstanding, the exact involvement 
of DDR1 and DDR2 in CP and associated pancreatic fibrosis remains unclear and has not been studied yet. In 
CP, repetitive injury of the pancreas trigger release of variety of cytokines and chemokines, which results in the 
activation of collagen-producing PSCs accompanied by excessive accumulation of ECM.
Figure 5.  Effect of IMT on cerulein-induced pancreatic injury and inflammation. (A,B) Plasma amylase 
and lipase levels. (C) Representative photographs of H & E staining of pancreas at 400X magnification. (D,E) 
Western blot and corresponding densitometric analysis of protein expression of total and phosphorylated 
NF-κB in pancreas, (F–H) Pancreatic IL-1β, IL-6 and TNF-α levels studied by ELSA. β-actin was used as loading 
control. All values are represented as mean ± SEM (n = 7). Statistical significance was established using one-
way ANOVA followed by Tukey’s multiple comparisons test where ***P < 0.001 vs Normal control, #P < 0.05, 
##P < 0.01, ###P < 0.001 vs Cerulein. Full-length blots are presented in Supplementary Fig. S3.
Figure 6.  Effect of IMT on pancreatic stellate cells activation (PSCs). (A,B) Representative photographs of 
immunohistochemistry and quantitative analysis of α-SMA protein in the pancreatic tissue, (C,D) Western 
blot and corresponding densitometric analysis of protein expression of α-SMA, (E) Immunofluorescence (IF) 
staining for α-SMA in TGF-β1-induced PSCs. β-actin was used as loading control. All values are represented 
as mean ± SEM (n = 3–10). Statistical significance was established using one-way ANOVA followed by Tukey’s 
multiple comparisons test where ***P < 0.001 vs Normal control, ##P < 0.01, ###P < 0.001 vs Cerulein. Full-length 
blots are presented in Supplementary Fig. S4.
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The significant upregulation of DDRs was observed in the present study which suggested that these receptors 
play a major role in the development of pancreatic fibrosis. The results were consistent with previous literature 
where activation of DDR1 and DDR2 was found to be involved in the progression of fibrosis in kidney and 
 lungs8,34. In a recent study, Ruggeri et al. reported that overexpression of DDR1 plays a significant role during pan-
creatic injury, tumor development, and tumor  progression38. Based on our observations of increased expression of 
DDR1 and DDR2 in CP conditions, we have selected IMT as a potential inhibitor of these receptors on the basis 
of its well proven inhibitory effects on these two  receptors14. Moreover, being clinically available FDA approved 
drug, it may be relatively easy to develop this drug as possible therapy against CP. The significant inhibition of 
DDR1 and DDR2 by IMT observed in the present study suggested a strong link between DDRs and pancreatic 
fibrosis. Our results were found to be in correlation with previous studies showing role of DDRs in fibrosis, e.g., 
Moll et al., reported that pharmacological inhibition of DDR1 significantly inhibited fibrotic and inflammatory 
protein expression in the human crescentic  glomerulonephritis39. Another study demonstrated the reduction 
in the deposition of collagen in the kidneys of DDR1 null mice. In addition, Li et al. demonstrated that deletion 
of DDR2 significantly alleviated renal interstitial fibrosis induced by unilateral ureteral  obstruction40. In light of 
the results of present as well as previous studies, it was evident that DDRs play a major role in the progression of 
pancreatic fibrosis and the inhibition of these receptors could become a novel approach for the fibrotic disorders.
The inflammation is one of the most important factors involved in the initiation and progression of the 
fibrosis in different organs. In context of pancreatic injury, the inflammatory cells infiltration along with acinar 
cell atrophy are major players in the  CP41. Although, the DDRs are essential for normal development and tissue 
homeostasis; the overexpression of these receptors is associated with tissue  injury42. Similarly, we also observed 
marked pancreatic injury and histopathological alterations including atrophy of acinar cells, vacuolization, infil-
tration of inflammatory cells along with induced expression of DDRs. However, the inhibition of DDR1 and 
DDR2 resulted in reduced pancreatic injury and histopathological alterations in the present study. Our results 
were consistent with the earlier reports where DDRs were reported to be involved in the regulation of tissue 
homeostasis, cell proliferation, migration and remodeling of the ECM in the injured  pancreas38. In addition, we 
found that CP mice showed activated NF-κB signaling accompanied with elevation of inflammatory mediators 
namely, TNF-α, IL-1β and IL-6 in the pancreas. There is a high possibility that this increased inflammatory 
Figure 7.  Effect of IMT on TGF-β1/Smad signaling pathway. (A–D) Western blot and corresponding 
densitometric analysis of protein expression of phosphorylated and total Smad2/3, TGF-β1 and CTGF in 
pancreatic tissue, (E) Pancreatic TGF-β1 levels studied by ELISA. (F) IF staining for phosphorylated Smad2/3 
in TGF-β1-induced PSCs. β-actin was used as loading control. All values are represented as mean ± SEM (n = 3). 
Statistical significance was established using one-way ANOVA followed by Tukey’s multiple comparisons test 
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process could be due to the elevated DDR1 and DDR2 expression as the previous reports showed that DDR1 
and DDR2 activation was accompanied by the induction of pro-inflammatory  cytokines42,43. It is highly likely 
that DDR1 and DDR2 could specifically initiate the release of several inflammatory mediators by the activation 
of NF-κB in CP pancreas. On the other hand, the inhibition of DDR1 and DDR2 showed anti-inflammatory 
potential via successful inhibition of the inflammatory signaling in CP mice further supporting the association 
of DDRs with  inflammation35,44.
PSCs are the major effector cells which play a central role in the progression and development of pancreatic 
fibrosis in response to persistent  injury45. PSCs activate and proliferate in response to profibrotic cytokines 
such as TGF-β1, CTGF and  PDGF46. Activated PSCs show induced expression of α-SMA and increases the 
accumulation of ECM proteins including collagens type I and III, and  fibronectin47. In fact, the activation of 
PSCs has been observed in pancreatic injury of humans as well as animals. Haber et al., demonstrated that PSCs 
are activated in the experimental and human pancreatic  fibrosis48. In the light of previous study, we observed 
activation of PSCs in CP mice which could be due to the upregulation of DDR1 and DDR2 proteins. Grow-
ing evidences showed that excessive deposition of collagen type I and III activates DDR1 and DDR2 signaling 
which then induces proliferation and activation of  myofibroblasts49,50. Similarly, we found that pharmacological 
inhibition of DDR1 and DDR2 significantly blunted PSCs activation and ECM deposition. Our results were 
complying with the earlier literature, where inhibition of DDR1 and DDR2 prevented the fibroblast prolifera-
tion and  migration30,51. These results suggest that the suppression of PSCs activation and ECM markers might 
be the result of the downregulated DDRs’ expression, which ultimately resulted in the attenuation of pancreatic 
fibrosis. Our findings imply that inhibition of DDR1 and DDR2 could be an attractive molecular target for the 
prevention of PSCs activation and pancreatic fibrosis.
Growing number of evidences report that TGF-β1 plays a phenomenal role in all types of fibrotic diseases 
including pancreatic fibrosis. It is the main mediator for the activation of PSCs which subsequently increases 
deposition of ECM  proteins29. TGF-β1 binds to its receptors expressed by PSCs and initiates its fibrotic responses 
through the activation of Smad pathway. In addition, our earlier studies reported that activation of TGF-β/Smad 
stimulates PSCs activation and consequently results in the progression of the pancreatic  fibrosis18,25. In context 
with CP, researchers have documented that there is an activation of TGF-β1/Smad signaling in response to the 
overexpression of DDR1/DDR252, but its role in the regulation of TGF-β1/Smad signaling and PSCs activation 
in CP has not been explored. In accordance with the earlier reports, we observed the activation of TGF-β1 and 
its downstream mediators, which might be due to the upregulation of DDR1 and DDR2 expression in CP. Our 
results are in accordance with the previous study showing that DDR1 interacts with TGF-β1 pathway to restrict 
calcifying extracellular vesicle-mediated mineralization and fibrosis in vascular smooth muscle  cells53. Further, 
studies have also demonstrated that genetic deletion of DDR1 is directly associated with the downregulation of 
TGF-β and CTGF in renal  fibrosis43,54. In addition, Zhao et al., reported that upregulation of DDR2 activates the 
TGF-β signaling, while DDR2 knockdown resulted in the inhibition of TGF-β signaling in lung  fibroblasts34. 
Consistent with these findings, we observed that pharmacological inhibition of DDR1 and DDR2 effectively 
inhibited TGF-β1 and subsequent Smad signaling. Here, our results suggested that DDRs are involved in the 
activation of TGF-β/Smad signaling and pharmacological inhibition of DDRs attenuated pancreatic fibrosis by 
inhibiting TGF-β/Smad signaling (Fig. 8). The limitation of our study is that due to unavailability of selective 
Figure 8.  Schematic diagram of the molecular mechanisms of discoidin domain receptors (DDR1/DDR2) 
in the activation of pancreatic stellate cells (PSCs) and progression of pancreatic fibrosis. During pancreatic 
injury, release of variety of inflammatory mediators and transforming growth factor (TGF)-β promotes the 
upregulation of expression of DDR1 and DDR2, which results in the activation of TGF-β1 downstream pathway 
and NF-κB signaling, consequently leading to excessive ECM deposition and pancreatic fibrosis. Moreover, IMT 
produced its protective effects by inhibiting DDR1/DDR2 signaling pathways in CP and associated fibrosis.
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inhibitors, we have chosen FDA approved clinically available IMT as a model inhibitor of DDR1/2 receptors, 
which also processes inhibitory effects on other tyrosine kinases. Nevertheless, the use of highly selective agents 
against DDR1 and 2 receptors along with gene silence and knockout models may provide better molecular 
understanding on these novel targets to explore for chronic pancreatitis therapy.
Conclusion
Taken together, the data from this study strongly provides evidences that activation of DDR1 and DDR2 are 
predominantly implicated in the progression of CP and associated fibrosis. Further, upregulation of DDR1 
and DDR2 is involved in the enhancement of pancreatic injury, PSCs activation and TGF-β/Smad signaling. 
In addition, pharmacological inhibition of DDRs provided promising protective effects against CP and associ-
ated fibrosis. In the light of our results, it was suggested that DDRs play a significant role in CP progression and 
targeting of DDRs could become a potential target for halting the progression of CP.
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